# A Dose Response Study of E6011 in Participants With Rheumatoid Arthritis Inadequately Responding to Methotrexate

> **NCT02960438** · PHASE2 · COMPLETED · sponsor: **Eisai Co., Ltd.** · enrollment: 273 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** E6011
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02960438
- **Lead sponsor:** Eisai Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-20
- **Primary completion:** 2018-02-28
- **Final completion:** 2019-09-17
- **Target enrollment:** 273 (ACTUAL)
- **Last updated:** 2021-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02960438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02960438, "A Dose Response Study of E6011 in Participants With Rheumatoid Arthritis Inadequately Responding to Methotrexate". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02960438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*